Who is sponsoring NCT05349162?

NCT05349162 is sponsored by Paris Cardiovascular Research Center (Inserm U970).

What drugs are being tested in NCT05349162?

Interventions in NCT05349162: Implantable cardioverter defibrillator use.

Is NCT05349162 still recruiting?

NCT05349162 is currently completed. Last updated 27 April 2022.

Last reviewed 2022-04-27 · How we verify

NCT05349162

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Epicardial vs. Transvenous ICDs in Children

Completed Last updated 27 April 2022

What this trial tests

trial testing Implantable cardioverter defibrillator use in Implantable Cardioverter Defibrillator Complications in 131 participants. Completed in 1 April 2022.

Timeline

1 January 2003

Primary endpoint
1 January 2021

1 April 2022

Quick facts

Lead sponsor	Paris Cardiovascular Research Center (Inserm U970)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	131
Start date	1 January 2003
Primary completion	1 January 2021
Estimated completion	1 April 2022

Drugs / interventions tested

Implantable cardioverter defibrillator use

Conditions studied

Implantable Cardioverter Defibrillator Complications — all drugs for Implantable Cardioverter Defibrillator Complications →
Implantable Defibrillator User — all drugs for Implantable Defibrillator User →

Sponsor

Paris Cardiovascular Research Center (Inserm U970)

Who can join

Adults 0 to 18, any sex, with Implantable Cardioverter Defibrillator Complications or Implantable Defibrillator User. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This observational study included all patients \<18-year-old implanted with an Implantable cardioverter defibrillator (ICD) at Necker Hospital, Paris, France, from January 2003 to January 2021. Outcomes (ICD-related complications and reinterventions) were compared between epicardial and transvenous ICDs using Cox proportional hazard models.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Epicardial vs. transvenous implantable cardioverter defibrillators in children.
Le Bos PA, Pontailler M, Maltret A, Kraiche D, et al · · 2023 · cited 9× · PMID 36735263 · DOI 10.1093/europace/euad015

Verify or expand the search:

Other Paris Cardiovascular Research Center (Inserm U970) trials

Trials by the same sponsor.

NCT04205461 — Prospective Evaluation of Programmed Ventricular Stimulation Before Pulmonary Valve Replacement in Patients With Tetralo · unknown
NCT04202796 — Catheter Ablation in Congenital Heart Disease: French National Prospective Registry · unknown
NCT04842851 — Cardiac Resynchronization Therapy in Congenital Heart Diseases With Systemic Right Ventricle · completed
NCT07291544 — Management of Supraventricular Tachycardias in Children · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05349162 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Paris Cardiovascular Research Center (Inserm U970)
Last refreshed: 27 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05349162.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing